EVALUATION OF PRIMARY CUTANEOUS MALIGNANT MELANOMA ACCORDING TO BRESLOW AND CLARKE PATHOLOGICAL INDICES
暂无分享,去创建一个
[1] R. M. Mackie,et al. Disorders of the Cutaneous Melanocyte , 2008 .
[2] J. Kirkwood,et al. Update: current management issues in malignant melanoma. , 2005, Melanoma research.
[3] M. Berwick,et al. The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma , 2005, Journal of cutaneous pathology.
[4] M. Nicolson,et al. Incidence of and survival from malignant melanoma in Scotland: an epidemiological study , 2002, The Lancet.
[5] G. Plewig,et al. Prognostic index for cutaneous melanoma: an analysis after follow-up of 2715 patients , 2001, Melanoma research.
[6] P. Hutchinson,et al. Clinical correlates of Breslow thickness of malignant melanoma , 2001, The British journal of dermatology.
[7] A. Halpern,et al. A Prognostic Model for Predicting 10-Year Survival in Patients with Primary Melanoma , 1996, Annals of Internal Medicine.
[8] J. Melia,et al. Cancer Research Campaign health education programme to promote the early detection of cutaneous malignant melanoma. II. Characteristics and incidence of melanoma , 1995, The British journal of dermatology.
[9] L. Bucchi,et al. Analysis of Breslow Tumor Thickness Distribution of Skin Melanoma in the Italian Region of Romagna, 1986–1991 , 1994, Tumori.
[10] G. Lanzanova,et al. Breslow Thickness of Cutaneous Malignant Melanoma in Ravenna (Northern Italy) 1981–1990 , 1992, Tumori.
[11] D. Reintgen,et al. Recurrent malignant melanoma: the identification of prognostic factors to predict survival. , 1992, Annals of plastic surgery.
[12] A. Halpern,et al. Model predicting survival in stage I melanoma based on tumor progression. , 1989, Journal of the National Cancer Institute.
[13] A. Ragaz. Pathology of malignant melanoma. , 1982, The Journal of dermatologic surgery and oncology.
[14] A. Kopf,et al. Correlation of thicknesses of superficial spreading malignant melanomas and ages of patients. , 1981, The Journal of dermatologic surgery and oncology.